{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RTV+Placebo", "query": { "intervention": "RTV Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RTV+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T12:33:43.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01108510", "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2010-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01108510" }, { "nct_id": "NCT04933799", "title": "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pneumonia" ], "interventions": [ { "name": "PF-06650833", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giovanni Franchin, M.D, Ph.D", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2021-01-06", "completion_date": "2022-05-06", "has_results": false, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933799" }, { "nct_id": "NCT02511431", "title": "Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis D" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2015-07-29", "completion_date": "2017-02-23", "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511431" }, { "nct_id": "NCT05605093", "title": "Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Shionogi Protease Inhibitor (S-217622)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2022-12-23", "completion_date": "2025-10-28", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 103, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05605093" }, { "nct_id": "NCT00197145", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-07-21", "completion_date": "2007-09-11", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Laguna Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197145" }, { "nct_id": "NCT00708162", "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Elvitegravir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "EVG placebo", "type": "DRUG" }, { "name": "RAL placebo", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2008-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 94, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708162" }, { "nct_id": "NCT00197197", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-07", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2011-03-29", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 11, "location_summary": "Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197197" }, { "nct_id": "NCT02795754", "title": "Single and Repeated Dose Escalation Study of GSK2838232", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2838232 PIB", "type": "DRUG" }, { "name": "GSK2838232 IR1", "type": "DRUG" }, { "name": "GSK2838232 IR2", "type": "DRUG" }, { "name": "Placebo PIB", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 62, "start_date": "2016-03", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-18", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02795754" }, { "nct_id": "NCT01345630", "title": "Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir", "type": "DRUG" }, { "name": "darunavir/ritonavir 800/100 mg", "type": "DRUG" }, { "name": "placebo for emtricitabine/tenofovir", "type": "DRUG" }, { "name": "placebo for maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 813, "start_date": "2011-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 84, "location_summary": "Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hobson City", "state": "Alabama" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01345630" }, { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of COVID-19", "Long COVID" ], "interventions": [ { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Paxlovid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2026-06-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-03T12:33:43.839Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07597902" } ] }